# Thairm Bio

> Thairm Bio is a VC fund backing Health Care, Biotechnology and Medical. See 12 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 12
- Last investment: Apr 2026
- Lead investor: 50%
- Last updated: Aug 2026

Thairm Bio is a Trust that invests in early-stage life science companies that show promise in developing breakthrough treatments for diseases with the potential to make a major improvement to patients' lives.

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $2M–$3.3M |
| Series A | $12M–$21M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 33% |
| Biotechnology | 3 | 25% |
| Medical | 2 | 17% |
| Women's | 1 | 8% |
| Internet | 1 | 8% |

9 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 2 | 17% |
| Series A | 2 | 17% |
| Funding Round | 2 | 17% |
| Venture - Series Unknown | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 4 | 33% |
| United States | 1 | 8% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| EnteroBiotix | EnteroBiotix is a developer of novel medicinal products intended to restore health and prevent bacterial infections. The company's offerings include developing and advancing novel microbiome-modulating drugs composed of bacterial communities derived directly from the human gastrointestinal tract associated with imbalances of bacteria in thehuman gut, enabling physicians to prevent and treat debilitating infections and diseases. | $25.7M | Venture - Series Unknown | Apr 29, 2026 | http://enterobiotix.com/ |
| 3Daughters | 3Daughters is a women’s healthcare company developing a new evolutionary intrauterine device (IUD) for contraception. | $2.7M | Seed | Jul 10, 2024 | https://www.3daughtershealth.com/ |
| Phlo | Phlo is a digital pharmacy delivering NHS & Private prescriptions when and where you need them. Phlo works with both repeat and acute (one-off) prescriptions.Phlo uses technology and analytics to place patients at the heart of our business, providing patients with real-time, on-demand delivery of their acute and repeat prescriptions.Phlowas established in January, 2019 in London, England by Nadeem Sarwar. | $11.2M | Venture - Series Unknown | Apr 17, 2024 | http://www.wearephlo.com |
| EnteroBiotix | EnteroBiotix is a developer of novel medicinal products intended to restore health and prevent bacterial infections. The company's offerings include developing and advancing novel microbiome-modulating drugs composed of bacterial communities derived directly from the human gastrointestinal tract associated with imbalances of bacteria in thehuman gut, enabling physicians to prevent and treat debilitating infections and diseases. | $29.3M | Series B | Apr 04, 2024 | http://enterobiotix.com/ |
| 3Daughters | 3Daughters is a women’s healthcare company developing a new evolutionary intrauterine device (IUD) for contraception. | $2M | Seed | Jan 22, 2024 | https://www.3daughtershealth.com/ |
| Microplate Dx | Microplate Dx is a developer of diagnostic technology aimed at significantly reducing fatalities caused by drug-resistant infections.Microplate Dx, an award-winning spinout company from the University of Strathclyde in Glasgow, focuses on creating innovative diagnostic solutions to combat the significant global health challenge of antimicrobialresistance. Their technology revolves around the ingenious concept of employing highly sensitive biosensor electrodes, enhanced with miniaturized hydrogel deposits containing various antibiotics tailored to the specific infection being detected. The primary mission of Microplate DX is to proactively prevent and manage the proliferation of antimicrobial resistance on a global scale. | $3.3M | Seed | Sep 11, 2023 | https://microplatedx.com/ |
| Pneumagen | Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilitiesin glycobiology. | $10M | Venture - Series Unknown | Jun 01, 2023 | https://www.pneumagen.com/ |
| Phlo | Phlo is a digital pharmacy delivering NHS & Private prescriptions when and where you need them. Phlo works with both repeat and acute (one-off) prescriptions.Phlo uses technology and analytics to place patients at the heart of our business, providing patients with real-time, on-demand delivery of their acute and repeat prescriptions.Phlowas established in January, 2019 in London, England by Nadeem Sarwar. | $12.2M | Series A | Feb 02, 2023 | http://www.wearephlo.com |
| Pneumagen | Pneumagen focuses on developing glycan targeted carbohydrate-binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer. Founded in 2016, the Company is a spin-out from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilitiesin glycobiology. | $5.2M | Venture - Series Unknown | Jan 19, 2022 | https://www.pneumagen.com/ |
| EnteroBiotix | EnteroBiotix is a developer of novel medicinal products intended to restore health and prevent bacterial infections. The company's offerings include developing and advancing novel microbiome-modulating drugs composed of bacterial communities derived directly from the human gastrointestinal tract associated with imbalances of bacteria in thehuman gut, enabling physicians to prevent and treat debilitating infections and diseases. | $21.4M | Series A | Sep 07, 2021 | http://enterobiotix.com/ |

10 of 12 investments shown.

## Co-investors
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund, 9 deals together
- [Argosy Foundation](https://shizune.co/investors/profile/argosy-foundation) — VC Fund, 2 deals together
- [Kineticos Ventures](https://shizune.co/investors/profile/kineticos-ventures) — VC Fund, 2 deals together
- [Scottish Investment Bank](https://shizune.co/investors/profile/scottish-investment-bank) — VC Fund, 2 deals together
- [Scottish National Investment Bank](https://shizune.co/investors/profile/scottish-national-investment-bank) — VC Fund, 2 deals together
- [SIS Ventures](https://shizune.co/investors/profile/sis-ventures) — VC Fund, 2 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Gaingels](https://shizune.co/investors/profile/gaing) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Wellness Investors in United Kingdom](https://shizune.co/investors/wellness-investors-united-kingdom)

## FAQ

### What does Thairm Bio invest in?

Thairm Bio invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 12 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Thairm Bio's check size?

Thairm Bio typically joins rounds of $2M–$3.3M at Seed and $12M–$21M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Thairm Bio participates in.

### When did Thairm Bio last invest?

The most recent investment recorded for Thairm Bio closed in Apr 2026. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co